Novo's next-gen obesity drug shows positive results, heads to late-stage testing

Novo Nordisk said connected Tuesday its experimental obesity drug, amycretin, showed statistically important value nonaccomplishment of up to 14.5% astatine 36 weeks successful patients with benignant 2 diabetes successful a mid-stage study.

The drugmaker's Denmark-listed shares were up 2.5%.

Amycretin, the company's next-generation obesity drug, has a dual-mode action, targeting the gut hormone GLP-1 and a pancreatic hormone called amylin.

The survey tested once-weekly subcutaneous and oral amycretin compared to placebo successful 448 radical with benignant 2 diabetes inadequately controlled connected metformin with oregon without an SGLT2 inhibitor, a communal people of diabetes treatment, Novo said.

The information validates the imaginable best-in-class illustration of amycretin, said Martin Holst Lange, main technological serviceman and enforcement vice president of probe and improvement astatine Novo Nordisk.

The institution said the cause appeared harmless and good tolerated, with mostly mild-to-moderate gastrointestinal broadside effects. It plans to commencement late-stage trials successful 2026.

Amycretin is 1 of Novo's next-generation experimental drugs that mightiness let it to widen its net beyond its 2031-2032 semaglutide patent expiries, HSBC analysts had said successful a enactment earlier this year.

Weekly injections of amycretin had helped overweight patients suffer 22% of their value successful 36 weeks, according to early-stage proceedings results published successful January.

Last year, the pill mentation helped patients suffer up to 13.1% of their value aft 12 weeks successful an early-stage trial.